<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03038503</url>
  </required_header>
  <id_info>
    <org_study_id>ID 09-59-14</org_study_id>
    <nct_id>NCT03038503</nct_id>
  </id_info>
  <brief_title>What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin</brief_title>
  <official_title>What Should be the Next Vasopressor for Severe Septic Shock Patients? Methylene Blue or Terlipressin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramathibodi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ramathibodi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ICU mortality rate of patients with septic shock was still high upto 54.1%.In first 6
      hours of resuscitation, the goals of resuscitation in sepsis shock after adequate fluid
      resuscitation is MAP â‰¥65 mmHg. In refractory septic shock patient, prolong shock correlate
      with poor outcome due to multiple organ failure. Alternative vasopressor in septic shock with
      catecholamine resistance has been studied such as terlipressin, methylene blue

        -  Terlipressin (TP) mediate vasoconstriction via V1 receptors coupled to phospholipase C,
           and increases intracellular Ca2+ concentration

        -  Methylene blue (MB) directly inhibits nitric oxide synthase (NOS) by inhibit the enzyme
           guanylate cyclase (GC)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality rate</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time to wean of vasopressor</measure>
    <time_frame>through complete weaning off vasopressor, an average of 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU duration</measure>
    <time_frame>through out off indication need ICU care, an average of 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hemodynamic parameter: Mean arterial pressure (mmHg)</measure>
    <time_frame>every 30 min after start protocol up to 6 hr then every 1 hr up to 24 hours</time_frame>
    <description>mmHg, A-line monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemodynamic parameter: lactate (mmol/l)</measure>
    <time_frame>every 2 hr until 6 hr then every 4 hr until wean off vasopressor up to 24 hours</time_frame>
    <description>mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemodynamic parameter: urine output (ml)</measure>
    <time_frame>every 2 hr until wean off vasopressor up to 24 hours</time_frame>
    <description>ml</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Septic Shock</condition>
  <condition>Refractory Shock</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard care septic shock according sepsis bundles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>after defined refractory shock (adequate fluid resuscitation + add NE&gt;0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>after defined refractory shock (adequate fluid resuscitation + add NE&gt;0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <description>after defined refractory shock (need NE&gt;0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>after defined refractory shock (need NE&gt;0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;15 years old

          -  Diagnosis septic shock as SCCM/ACCP

          -  Refractory septic shock defined as hypotension although adequate fluid resuscitate and
             high dose vasopressor(NE &gt;0.5 mcg/kg/min)

          -  Concent form

        Exclusion Criteria:

          -  Known case G6PD deficiency

          -  Acute respiratory distress syndrome (ARDS)

          -  Hx of drug allergy MB, NE, terlipressin

          -  Hx of Raynaud's phenomenon, systemic sclerosis, PHT

          -  Known case coronary heart disease without treatment

          -  Current drug use serotonin reuptake inhibitors (SSRI), Serotonin and norepinephrine
             reuptake inhibitors (SNRIs)

          -  Reject to join project
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>viratch tangsujaritvijit, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>munthana sundusadee, MD</last_name>
    <phone>66639010178</phone>
    <email>opal_janeway@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ramathibodi hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>066</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>munthana sundusadee, md</last_name>
      <phone>66639010178</phone>
      <email>opal_janeway@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>January 28, 2017</last_update_submitted>
  <last_update_submitted_qc>January 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ramathibodi Hospital</investigator_affiliation>
    <investigator_full_name>munthana sundusadee</investigator_full_name>
    <investigator_title>fellowship in department of pulmonary and critical care department</investigator_title>
  </responsible_party>
  <keyword>refractory septic shock</keyword>
  <keyword>catecholamine resistance septic shock</keyword>
  <keyword>terlipressin</keyword>
  <keyword>methylene blue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

